Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a belgian context

Applied Health Economics and Health Policy

Volumn 6, Issue 1, 2008, Pages 67-80

  Neyt, Mattias ^a   Thiry, Nancy ^a   Ramaekers, Dirk ^a   Van Brabandt, Hans ^a  

^a BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

Cost effectiveness; Disease prevention; Implantable cardioverter defibrillators; Markov model

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEFIBRILLATOR; HEALTH CARE POLICY; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; PRIMARY PREVENTION; SUDDEN DEATH;

AGED; BELGIUM; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS;

EID: 51849086435     PISSN: 11755652     EISSN: 11755652     Source Type: Journal    
DOI: 10.2165/00148365-200806010-00006     Document Type: Article

References (21)

1. Bryant J, Brodin H, Loveman E, et al. The clinical and cost-effectiveness of implantable cardioverter defibrillators: a systematic review. Health Technol Assess 2005 Sep; 9 (36): 1-150, iii
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001 Nov 15; 345 (20): 1473-82
3. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 Jan 20; 352 (3): 225-37
4. Guidant. "Perceptions & reality": training manual for Guidant representatives. Economics of ICD therapy: a healthcare system perspective. Diegem: Guidant, 2005
5. Van Brabandt H, Thiry N, Neyt M, et al. De Implanteerbare defibrillator: een health technology assessment. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2007. Report no.: D2007/10.273/21
6. Fletcher J. What is heterogeneity and is it important? BMJ 2007 Jan 13; 334 (7584): 94-6
7. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 Mar 21; 346 (12): 877-83
8. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006 Sep; 27 (17): 2099-140
9. Cleemput I, Crott R, Vrijens F, et al. Recommandations provisoires pour les évaluations pharmacoéconomiques en Belgique. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE), 2006. Report no.: 28B
10. Institute for Clinical System Improvement (ICSI). Implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death due to ventricular arrhythmias. Bloomington (MN): ICSI, 2005
11. Medical Services Advisory Committee (MSAC). Implantable cardioverter defibrillators for prevention of sudden cardiac death. MSAC Reference 32. Canberra (ACT): MSAC, 2006
12. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006 Jul 11; 114 (2): 135-42
13. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
14. Federal Public Service Economy, SMEs, Self-employed and Energy. Key figure, indices [online]. Available from URL: http://www.mineco.fgov.be/ informations/indexes [Accessed 2008 Aug 29]
15. Belgian Centre for Pharmacotherapeutic Information. Price table, class III anti-arrhythmics [online]. Available from URL: http://www.bcfi.be/ggr/index. cfm?ggrWelk=/nindex/ggr/stof/IN_A.cfm [Accessed 2007 May 24]
16. Hlatky MA, Mark DB. The high cost of implantable defibril lators. Eur Heart J 2007 Feb; 28 (4): 388-91
17. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005 Oct 6; 353 (14): 1471-80
18. Rice JA. Mathematical statistics and data analysis. Belmont (CA): Duxbury Press, 1995
19. Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics 2005; 23 (5): 423-32
20. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004. Report no.: N0515
21. Hauser RG. The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. J Am Coll Cardiol 2005 Jun 21; 45 (12): 2022-5